Patient Profile Presentation: A 72-Year-Old Man Presenting with Hematuria

Video

Dr Shawnta Anakwah presents the patient profile of a 72-year-old man with advanced renal cell carcinoma presenting with hematuria.

Shawnta Anakwah, MD: The last case is a 72-year-old man who presented with hematuria. A CT scan showed an 8.5-cm left-sided renal mass with suspicious mediastinal lymphadenopathy. His past medical history consisted of hypertension; well-controlled, diet-controlled diabetes; and psoriasis, which did not require any medical therapy. He was on blood pressure medicines and an aspirin.

The decision was made to pursue a radical nephrectomy. He underwent surgery, and he was found to have a T3 clear cell renal cell carcinoma. He did have 2 of 10 lymph nodes involved. He did not have any rhabdoid features, but he did have 20% sarcomatoid features. The mediastinal lymph node was biopsied, and it was confirmed to be metastatic clear cell RCC [renal cell carcinoma]. From his labs on presentation, he had a slightly elevated white blood cell count of 12,000 per mm3, hemoglobin of 12.4 g/dL, platelet count of 210 per mm3, and normal calcium, and his other labs were unremarkable. He was deemed to have intermediate-risk clear cell RCC because of his metastatic disease within 1 year of nephrectomy and his leukocytosis.

The patient was started on cabozantinib with nivolumab, 480 mg, every 4 weeks. At his 3-month scan, he was found to have a partial response in his mediastinal lymph nodes. But by his 6-month scan, he had a complete response [CR] with normalization of his target mediastinal lymph nodes. At 12 months, the patient still has an ongoing CR. He did have some toxicities. His blood pressure was elevated, so he was able to tolerate the addition of a calcium channel blocker. He developed a grade 1 skin rash, which was treated with topical steroid cream.

Arnab Basu, MD: Great. There’s a good outcome for this gentleman.

Shawnta Anakwah, MD: Yes.

Transcript edited for clarity.

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Wenxin (Vincent) Xu, MD,
Related Content
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024
Article
John McGrane, MD, consultant oncologist, Royal Cornwall Hospitals NHS Trust

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024
Article